載入...
The transdermal formulation of rivastigmine improves caregiver burden and treatment adherence of patients with Alzheimer's disease under daily practice conditions
BACKGROUND: Rivastigmine is the only cholinesterase inhibitor (ChEI) available as transdermal patch. The patch was developed to improve gastrointestinal tolerability and treatment adherence to higher dosages as compared with oral medication. Preferences of patients and caregivers for the patch were...
Na minha lista:
| 發表在: | Int J Clin Pract |
|---|---|
| Main Authors: | , , |
| 格式: | Artigo |
| 語言: | Inglês |
| 出版: |
BlackWell Publishing Ltd
2014
|
| 主題: | |
| 在線閱讀: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4237461/ https://ncbi.nlm.nih.gov/pubmed/24588972 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/ijcp.12374 |
| 標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|